Thomas A Mavrakanas
Overview
Explore the profile of Thomas A Mavrakanas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Travlos C, Chirgwin-Dasgupta A, Trinh E, Sniderman A, Alam A, Mavrakanas T
Clin Kidney J
. 2025 Feb;
17(12):sfae347.
PMID: 39981320
Background: Patients with kidney failure on maintenance dialysis have a high stroke and bleeding risk. Multivariable prediction models can be used to estimate the risk of ischemic stroke and bleeding....
2.
Konecki C, Lipman M, Mavrakanas T, Djerada Z
Clin Pharmacokinet
. 2025 Jan;
64(2):307-321.
PMID: 39853633
Background And Objective: Apixaban is increasingly being used for stroke prevention in patients with end-stage kidney disease with atrial fibrillation undergoing haemodialysis, but no pharmacostatistical model is available for dosage...
3.
Riedl Khursigara M, Liu P, Kaur R, Mavrakanas T
Can J Kidney Health Dis
. 2024 Nov;
11:20543581241293500.
PMID: 39502166
Purpose Of Review: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are glucose lowering agents with protective effects on cardiovascular health and the ability to slow chronic kidney disease (CKD) progression. The benefits of...
4.
Harel Z, Smyth B, Badve S, Blum D, Beaubien-Souligny W, Silver S, et al.
J Am Soc Nephrol
. 2024 Nov;
PMID: 39495569
No abstract available.
5.
Marques P, Vasques-Novoa F, Matias P, Vieira J, Mavrakanas T, Sharma A, et al.
Clin Res Cardiol
. 2024 Oct;
PMID: 39432015
Background: Intravenous iron improves symptoms in heart failure (HF) with iron deficiency (ID) but failed to consistently show a benefit in cardiovascular outcomes. The ID definition used may influence the...
6.
Mavrakanas T, Marsot A, Tsirella E, Rios N, Gritsas A, Suri R
Kidney Int Rep
. 2024 Oct;
9(10):3049-3052.
PMID: 39430196
No abstract available.
7.
Razaghizad A, Ni J, Marques P, Mavrakanas T, Tsoukas M, Possik E, et al.
Diabetes Obes Metab
. 2024 Sep;
26(11):5025-5035.
PMID: 39301712
Aim: To identify unique clinical phenotypes in type 2 diabetes (T2D) and investigate their treatment response to canagliflozin using latent class analysis. Methods: This was a pooled latent class analysis...
8.
Marques P, Mavrakanas T, Guida J, Gedeon T, Emami A, Alaamiri A, et al.
Diabetes Obes Metab
. 2024 Jun;
26(8):3448-3457.
PMID: 38831564
Aim: The management of patients with type 2 diabetes is asynchronous, i.e. not coordinated in time, resulting in delayed access to care and low use of guideline-directed medical therapy (GDMT)....
9.
Wing S, Mavrakanas T, Harel Z
Semin Nephrol
. 2024 May;
44(2):151517.
PMID: 38744617
Atrial fibrillation (AF) is highly prevalent in patients with chronic kidney disease (CKD). It is associated with an increased risk of stroke, which increases as kidney function declines. In the...
10.
Bortolussi-Courval E, Podymow T, Battistella M, Trinh E, Mavrakanas T, McCarthy L, et al.
Kidney Med
. 2024 Apr;
6(5):100810.
PMID: 38628463
Rationale & Objective: Patients treated with dialysis are commonly prescribed multiple medications (polypharmacy), including some potentially inappropriate medications (PIMs). PIMs are associated with an increased risk of medication harm (eg,...